pentobarbital will lessen the extent or outcome of elbasvir/grazoprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic effect of elbasvir/grazoprevir may be lowered if coadministered with powerful CYP3A inducers and it is hence contraindicated.Contraindicated (one)pentobarbital will minimize the level or